by James Lyons-Weiler, PhD, Popular Rationalism, ©2026
(Feb. 12, 2026) — We suspect that Moderna’s refusal is an attempt to avoid giving FDA the data it needs for age-specific approval and recommendation by restricting its options to proceeding in a way that would force the FDA to lower its standards. FDA called Moderna’s $750M bluff.
The U.S. Food and Drug Administration has announced it is refusing to even review Moderna’s application for its new mRNA-based influenza vaccine, mRNA-1010. In a refusal-to-file (RTF) letter, regulators cited a fundamental flaw in Moderna’s Phase 3 trial design as the sole reason for turning away the application. The crux of the issue is Moderna’s choice of comparator vaccine in its efficacy trials – a choice FDA now deems inconsistent with the requirement for “adequate and well-controlled” studies. This assertive move by the FDA has sent shockwaves through the biotech industry, with accusations of shifting regulatory goalposts.
This analysis will dissect the situation with an analytically rigorous lens. We will examine the FDA’s cited regulatory standard (21 CFR 314.126) and whether Moderna’s trial met it, identify methodological weaknesses in Moderna’s study design, and scrutinize the claim that FDA changed its criteria midstream. We will also place this decision in the broader context of current U.S. vaccine policy – notably a recent rollback of routine immunization guidance – and evaluate Moderna CEO Stéphane Bancel’s public response for accuracy and logic. Along the way, we’ll reference FDA regulations, clinical trial standards, and historical vaccine approvals to ground the discussion in evidence. The goal is not to take sides, but to expose flawed arguments and highlight discrepancies between regulatory standards and the actions of both Moderna and the FDA, in a rationalist tone that values facts over rhetoric.
Regulatory Standard: What Counts as “Adequate and Well-Controlled”?
At the heart of this dispute is FDA’s invocation of the requirement that new drug/vaccine approvals be supported by “adequate and well-controlled” trials (21 CFR 314.126). This regulation, which governs the quality of evidence needed for drug approval, lays out fundamental principles of sound clinical trial design. In essence, a trial must be designed to distinguish the effect of the product from other influences and allow a valid comparison to a control. Controls can be placebo, no-treatment, dose comparison, or an active comparator (an existing effective therapy). When an active control is used, the regulation expects it to be a known effective therapy for the condition. This ensures the study isn’t biased by comparing the new drug to something ineffective or substandard.
In Moderna’s case, the FDA letter argued that the chosen comparator did not represent the best available standard of care, rendering the study not “adequate and well-controlled” by their interpretation. More importantly, 21 CFR 314.126 defines the characteristics of an “adequate and well-controlled” study whose primary purpose is “to distinguish the effect of the drug from other influences, such as spontaneous change in the course of the disease, placebo effect, or biased observation.” The regulation requires a clear statement of objectives, a study design that “permits a valid comparison with a control to provide a quantitative assessment of drug effect,” randomization, blinding when feasible, and methods to minimize bias.
For adults 65 and older — the highest-risk group for severe influenza — the current U.S. standard of care (per ACIP) is no longer a standard-dose vaccine. High-dose, adjuvanted, and recombinant formulations have demonstrated superior performance in this population and are preferentially recommended precisely because they reduce more cases and complications than standard-dose shots. Comparing a new vaccine only to a weaker, non-preferred option creates a biased yardstick: it inflates the apparent relative benefit and fails to show whether the new product is truly an advance over the vaccines that seniors should be receiving today.
Read the rest here.